Quarterly ResultAug 6, 2026, 07:02 AM
Intellia: Positive Lonvo-z Phase 3 Data; BLA Expected H2 2026
AI Summary
Intellia Therapeutics reported positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema (HAE), showing an 87% reduction in attacks versus placebo. The company anticipates FDA acceptance of its Biologics License Application (BLA) for lonvo-z in H2 2026, with a U.S. launch planned for H1 2027. Additionally, enrollment for nex-z Phase 3 trials was reinitiated, and the company ended Q2 2026 with $628.4 million in cash, funding operations into 2028. The net loss for Q2 2026 was $106.6 million.
Key Highlights
- Lonvo-z Phase 3 HAELO trial met primary endpoint with 87% attack reduction vs. placebo.
- 62% of lonvo-z patients were attack-free and therapy-free for six months.
- Anticipate FDA BLA acceptance for lonvo-z in H2 2026; U.S. launch H1 2027.
- Enrollment reinitiated for nex-z Phase 3 trials; MAGNITUDE-2 enrollment expected H2 2026.
- Cash, cash equivalents, and marketable securities totaled $628.4 million as of June 30, 2026.
- Net loss for Q2 2026 was $106.6 million, compared to $101.3 million in Q2 2025.
- R&D expenses decreased to $82.6 million in Q2 2026 from $97.0 million in Q2 2025.
- G&A expenses increased to $37.8 million in Q2 2026 from $27.2 million in Q2 2025.
Price Impact
More from NTLA